Corticosteroids in Pediatric Septic Shock: A Narrative Review

Кортикостероиды при септическом шоке у детей: нарративный обзор
Eloisa Gitto, Roberto Chimenz, Immacolata Rulli, Angelo Mattia Carcione, Federica D’Amico, Giuseppa Quartarone
2024-12-17

Surviving Sepsis Campaigncorticosteroid therapycritical illness-related corticosteroid insufficiencyhydrocortisonepediatric septic shock
Objective: A controversial aspect of pediatric septic shock management is corticosteroid therapy. Current guidelines do not recommend its use in forms responsive to fluids and inotropes but leave the decision to physicians in forms refractory to the first steps of therapy. Data Sources: Review of literature from January 2013 to December 2023 from online libraries Pubmed, Medline, Cochrane Library, and Scopus. Study Selection: The keywords “septic shock”, “steroids” and “children” were used. Data Extraction: Of 399 articles, 63 were selected. Data Synthesis: Regarding mortality, although the 2019 Cochrane review supports reduced mortality, benefits on long-term mortality and in patients with CIRCI (critical illness-related corticosteroid insufficiency) are not clear. Yang’s metanalysis and retrospective studies of Nichols and Atkinson show no difference or even an increase in mortality. Regarding severity, the Cochrane review claims that hydrocortisone seems to reduce the length of intensive care hospitalization but influences the duration of ventilatory and inotropic support, and the degree of multi-organ failure appears limited. Further controversies exist on adrenal function evaluation: according to literature, including the Surviving Sepsis Campaign guidelines, basal or stimulated hormonal dosages do not allow the identification of patients who could benefit from hydrocortisone therapy (poor reproducibility). Regarding side effects, muscle weakness, hypernatremia, and hyperglycemia are the most observed. Conclusions: The literature does not give certainties about the efficacy of corticosteroids in pediatric septic shock, as their influence on primary outcomes (mortality and severity) is controversial. A subgroup of patients suffering from secondary adrenal insufficiency could benefit from it, but it remains to be defined how to identify and what protocol to use to treat them.
1
Among 399 screened articles, 63 studies were selected from literature published between January 2013 and December 2023.
2
Basal and stimulated adrenal hormone measurements have poor reproducibility and do not reliably identify children likely to benefit from hydrocortisone.
3
Current guidelines advise against corticosteroids in fluid- and inotrope-responsive pediatric septic shock, while leaving their use discretionary in refractory cases.
4
Evidence on mortality is inconsistent: the 2019 Cochrane review suggests reduced mortality, whereas other meta-analyses and retrospective studies report no benefit or potentially increased mortality.
5
Hydrocortisone may shorten intensive care hospitalization, but effects on ventilatory support, inotropic support, and multi-organ failure appear limited or uncertain.
6
Overall, corticosteroid efficacy remains uncertain; a subgroup with secondary adrenal insufficiency may benefit, but optimal identification and treatment protocols are undefined.
7
Reported corticosteroid adverse effects most commonly include muscle weakness, hypernatremia, and hyperglycemia.

pediatric septic shock

the efficacy, clinical outcomes, patient selection, and adverse effects of corticosteroid therapy, particularly hydrocortisone

Publication Details
Publication Date
2024-12-17
Journal
Publisher
ISSN
Cited by
10
Access Type
Author Information
Authors
Eloisa Gitto
Roberto Chimenz
Immacolata Rulli
Angelo Mattia Carcione
Federica D’Amico
Giuseppa Quartarone
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%